REZOLV3R | ACTRN12624000288527

The REZOLV3R trial compares post treatment paracentesis free survival time between each treatment group (bevacizumab or control).  The aim is to improve quality of life and optimise management of patients with advanced cancers with recurrent malignant ascites in the [...]

REZOLV3R | ACTRN126240002885272026-02-11T08:48:14+11:00

DOVE | APGOT-OV7/ENGOT-ov80

The DOVE trial is a Phase II, randomised study evaluating the efficacy and safety of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynaecological clear cell carcinoma.

DOVE | APGOT-OV7/ENGOT-ov802025-09-11T16:18:58+10:00

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812024-07-19T11:32:01+10:00

ENDO-3 | NCT04073706

ENDO-3 is a randomised controlled trial that compares sentinel lymph node dissection, a commonly performed procedure for the surgical staging of endometrial cancer, to no node dissection. The outcomes from this trial will provide high-level evidence on sentinel lymph node [...]

ENDO-3 | NCT040737062024-07-09T17:00:57+10:00
Go to Top